ORBIMED ADVISORS LLC — Form 4 insider transactions
ORBIMED ADVISORS LLC — Full 13F portfolio →
Buys and sells reported on SEC Form 4 — filed within two business days of each trade when a filer's ownership in a stock crosses 10%. This is the fastest public window into what the manager is doing.
| Transaction date | Activity | Security | Shares | Price | Total | Filing |
|---|---|---|---|---|---|---|
| 2026-11-10 | Buy | Electra Therapeutics, Inc. | 2,000 | $8.45 | $16,900 | SEC filing |
| 2026-11-10 | Buy | Electra Therapeutics, Inc. | 20,700 | $8.45 | $174,915 | SEC filing |
| 2026-11-09 | Buy | Electra Therapeutics, Inc. | 16,000 | $8.24 | $131,840 | SEC filing |
| 2026-11-09 | Buy | Electra Therapeutics, Inc. | 4,000 | $8.24 | $32,960 | SEC filing |
| 2026-11-06 | Buy | Electra Therapeutics, Inc. | 39,600 | $7.85 | $310,860 | SEC filing |
| 2026-11-06 | Buy | Electra Therapeutics, Inc. | 9,816 | $7.85 | $77,056 | SEC filing |
| 2026-11-05 | Buy | Electra Therapeutics, Inc. | 125,200 | $7.31 | $915,212 | SEC filing |
| 2026-11-05 | Buy | Electra Therapeutics, Inc. | 30,891 | $7.31 | $225,813 | SEC filing |
| 2026-11-04 | Buy | Electra Therapeutics, Inc. | 20,000 | $7.07 | $141,400 | SEC filing |
| 2026-11-04 | Buy | Electra Therapeutics, Inc. | 5,000 | $7.07 | $35,350 | SEC filing |
| 2026-11-04 | Buy | Electra Therapeutics, Inc. | 37,100 | $7.78 | $288,638 | SEC filing |
| 2026-11-04 | Buy | Electra Therapeutics, Inc. | 9,267 | $7.78 | $72,097 | SEC filing |
| 2026-11-03 | Buy | Electra Therapeutics, Inc. | 98,600 | $7.88 | $776,968 | SEC filing |
| 2026-11-03 | Buy | Electra Therapeutics, Inc. | 24,400 | $7.88 | $192,272 | SEC filing |
| 2026-11-03 | Buy | Electra Therapeutics, Inc. | 97,800 | $7.84 | $766,752 | SEC filing |
| 2026-11-03 | Buy | Electra Therapeutics, Inc. | 24,313 | $7.84 | $190,614 | SEC filing |
| 2026-11-02 | Buy | Aspen Neuroscience, Inc. | 1,000,000 | $15.00 | $15,000,000 | SEC filing |
| 2026-11-02 | Conversion | Aspen Neuroscience, Inc. | 507,119 | — | — | SEC filing |
| 2026-11-02 | Conversion | Aspen Neuroscience, Inc. | 625,743 | — | — | SEC filing |
| 2026-11-02 | Conversion | Aspen Neuroscience, Inc. | 616,984 | — | — | SEC filing |
| 2026-11-02 | Conversion | Aspen Neuroscience, Inc. | 642,745 | — | — | SEC filing |
| 2026-11-02 | Conversion | Aspen Neuroscience, Inc. | 196,541 | — | — | SEC filing |
| 2026-09-28 | Buy | ADARx Pharmaceuticals, Inc. | 588,235 | $17.00 | $9,999,995 | SEC filing |
| 2026-09-28 | Buy | ADARx Pharmaceuticals, Inc. | 61,516 | $17.00 | $1,045,772 | SEC filing |
| 2026-09-28 | Conversion | ADARx Pharmaceuticals, Inc. | 256,448 | — | — | SEC filing |
| 2026-09-28 | Conversion | ADARx Pharmaceuticals, Inc. | 513,067 | — | — | SEC filing |
| 2026-09-28 | Conversion | ADARx Pharmaceuticals, Inc. | 1,333,975 | — | — | SEC filing |
| 2026-09-28 | Conversion | ADARx Pharmaceuticals, Inc. | 7,127,019 | — | — | SEC filing |
| 2026-09-28 | Buy | ADARx Pharmaceuticals, Inc. | 300,249 | $17.00 | $5,104,233 | SEC filing |
| 2026-09-28 | Conversion | ADARx Pharmaceuticals, Inc. | 564,187 | — | — | SEC filing |
| 2026-09-28 | Conversion | ADARx Pharmaceuticals, Inc. | 769,601 | — | — | SEC filing |
| 2026-09-28 | Conversion | ADARx Pharmaceuticals, Inc. | 2,000,962 | — | — | SEC filing |
| 2026-09-28 | Conversion | ADARx Pharmaceuticals, Inc. | 10,690,530 | — | — | SEC filing |
| 2026-09-21 | Buy | Electra Therapeutics, Inc. | 1,000,000 | $15.00 | $15,000,000 | SEC filing |
| 2026-09-21 | Conversion | Electra Therapeutics, Inc. | 758,279 | — | — | SEC filing |
| 2026-09-21 | Buy | Electra Therapeutics, Inc. | 333,333 | $15.00 | $4,999,995 | SEC filing |
| 2026-09-21 | Conversion | Electra Therapeutics, Inc. | 1,703,314 | — | — | SEC filing |
| 2026-09-21 | Conversion | Electra Therapeutics, Inc. | 1,087,934 | — | — | SEC filing |
| 2026-09-21 | Conversion | Electra Therapeutics, Inc. | 2,002,310 | — | — | SEC filing |
| 2026-08-10 | Buy | BlossomHill Therapeutics, Inc. | 625,000 | $16.00 | $10,000,000 | SEC filing |
| 2026-08-10 | Conversion | BlossomHill Therapeutics, Inc. | 1,049,283 | — | — | SEC filing |
| 2026-08-10 | Conversion | BlossomHill Therapeutics, Inc. | 1,039,996 | — | — | SEC filing |
| 2026-08-07 | Buy | Braveheart Bio, Inc. | 273,333 | $18.00 | $4,919,994 | SEC filing |
| 2026-08-07 | Buy | Braveheart Bio, Inc. | 1,666,667 | $18.00 | $30,000,006 | SEC filing |
| 2026-08-07 | Conversion | Braveheart Bio, Inc. | 9,132,420 | — | — | SEC filing |
| 2026-07-27 | Buy | Scribe Therapeutics, Inc. | 1,000,000 | $15.00 | $15,000,000 | SEC filing |
| 2026-07-27 | Conversion | Scribe Therapeutics, Inc. | 348,825 | — | — | SEC filing |
| 2026-07-07 | Sell | Sionna Therapeutics, Inc. | 85,918 | $44.86 | $3,854,281 | SEC filing |
| 2026-06-30 | Sell | Sionna Therapeutics, Inc. | 115,844 | $45.50 | $5,270,902 | SEC filing |
| 2026-06-22 | Sell | Enliven Therapeutics, Inc. | 46,776 | $45.00 | $2,104,920 | SEC filing |
| 2026-06-22 | Sell | Enliven Therapeutics, Inc. | 787,024 | $45.38 | $35,715,149 | SEC filing |
| 2026-06-22 | Sell | Enliven Therapeutics, Inc. | 1,477 | $45.00 | $66,465 | SEC filing |
| 2026-06-22 | Sell | Enliven Therapeutics, Inc. | 24,846 | $45.38 | $1,127,511 | SEC filing |
| 2026-06-15 | Sell | Enliven Therapeutics, Inc. | 272,322 | $45.02 | $12,259,936 | SEC filing |
| 2026-06-15 | Sell | Enliven Therapeutics, Inc. | 9,086 | $45.02 | $409,052 | SEC filing |
| 2026-05-28 | Buy | Q32 Bio Inc. | 625,000 | $8.00 | $5,000,000 | SEC filing |
| 2026-05-28 | Buy | Q32 Bio Inc. | 1,250,000 | $8.00 | $10,000,000 | SEC filing |
| 2026-05-27 | Sell | Sionna Therapeutics, Inc. | 101 | $44.49 | $4,493 | SEC filing |
| 2026-05-11 | Sell | Sionna Therapeutics, Inc. | 184,639 | $46.22 | $8,534,015 | SEC filing |
| 2026-05-08 | Sell | Sionna Therapeutics, Inc. | 59,767 | $44.58 | $2,664,413 | SEC filing |
| 2026-05-07 | Sell | Sionna Therapeutics, Inc. | 48,546 | $44.61 | $2,165,637 | SEC filing |
| 2026-04-16 | Buy | Traws Pharma, Inc. | 597,729 | $1.67 | $998,207 | SEC filing |
| 2026-04-21 | Buy | Prelude Therapeutics Inc | 1,126,126 | $4.44 | $4,999,999 | SEC filing |
| 2026-04-21 | Buy | Prelude Therapeutics Inc | 1,689,189 | $4.44 | $7,499,999 | SEC filing |
| 2026-04-18 | Sell | Sionna Therapeutics, Inc. | 2,948 | $44.52 | $131,245 | SEC filing |
| 2026-04-17 | Sell | Sionna Therapeutics, Inc. | 52,397 | $44.68 | $2,341,098 | SEC filing |
| 2026-04-16 | Sell | Sionna Therapeutics, Inc. | 226,906 | $45.34 | $10,287,918 | SEC filing |
| 2026-04-15 | Sell | Sionna Therapeutics, Inc. | 235,863 | $44.64 | $10,528,924 | SEC filing |
| 2026-04-14 | Sell | Sionna Therapeutics, Inc. | 47,814 | $44.51 | $2,128,201 | SEC filing |
| 2026-04-08 | Sell | Adicet Bio, Inc. | 40,416 | $6.52 | $263,512 | SEC filing |
| 2026-04-08 | Sell | Adicet Bio, Inc. | 32,523 | $6.29 | $204,570 | SEC filing |
| 2026-04-07 | Sell | Adicet Bio, Inc. | 2,400 | $6.38 | $15,312 | SEC filing |
| 2026-04-07 | Sell | Adicet Bio, Inc. | 29,319 | $6.53 | $191,453 | SEC filing |
How Form 4 differs from 13F
13F filings are quarterly snapshots, up to 45 days late. Form 4 is transaction-level and lands within two business days — but only covers stocks where the filer reports beneficial ownership above 10%. Pair the two: 13F for the whole portfolio, Form 4 for what the largest holders are doing right now.